<scp>COVID</scp>‐19 of dialysis patients in Japan: Current status and guidance on preventive measures

Tadao Akizawa(Showa University), Yoshihiko Kanno(Tokyo Medical University), Hidetomo Nakamoto(Saitama Medical University), Ken Sakai(Japanese Society for Dialysis Therapy), Masaomi Nangaku(The University of Tokyo), Toshio Shinoda(Renal Association), Kan Kikuchi(Japanese Society for Dialysis Therapy), Norio Hanafusa(Nihon University), Ryoichi Ando(Doai Memorial Hospital), Tomoyuki Yamakawa(Toho University), Munekazu Ryuzaki(Saiseikai Central Hospital)
Therapeutic Apheresis and Dialysis
June 7, 2020
10.1111/1744-9987.13531
Cited by 68

Related Papers

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
|The Lancet|2021|997
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
|Kidney International|2016|474
An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013)
|Therapeutic Apheresis and Dialysis|2015|425